The Zacks Analyst Blog Highlights: Target, Wal-Mart Stores, Amazon.com, Best Buy and Abiomed

 The Zacks Analyst Blog Highlights: Target, Wal-Mart Stores, Amazon.com, Best
                               Buy and Abiomed

PR Newswire

CHICAGO, Aug. 12, 2013

CHICAGO, Aug. 12, 2013 /PRNewswire/ -- Zacks.com announces the list of stocks
featured in the Analyst Blog. Every day the Zacks Equity Research analysts
discuss the latest news and events impacting stocks and the financial markets.
Stocks recently featured in the blog include Target Corporation (NYSE:TGT-Free
Report), Wal-Mart Stores Inc. (NYSE:WMT-Free Report), Amazon.com Inc.
(Nasdaq:AMZN-Free Report), Best Buy Co. Inc. (NYSE:BBY-Free Report) and
Abiomed, Inc. (Nasdaq:ABMD-Free Report).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of
the Day pick for free.

Here are highlights from Friday's Analyst Blog:

Target to Expand Beauty Market

The online beauty industry is growing by leaps and bounds, and Target
Corporation (NYSE:TGT-Free Report) intends to leave no stone unturned in
making the most of this booming market. This is evident from its latest deal
to acquire DermStore Beauty Group, an online beauty retailer that would
further strengthen its footprint in this segment by enhancing its portfolio of
offerings. The financial terms of the deal, which is expected to conclude
within 60 days, were not revealed.

Target hinted that DermStore, which will become a wholly owned subsidiary,
will sustain its operation under the name DermStore.com. The transaction,
which is strategically important in the long run, amid a sluggish, competitive
economic environment, is not expected to have a favorable impact on the
company's fiscal-2013 results.

The current CEO of DermStore, Dan Obegi, will spearhead the wholly owned
subsidiary and directly report to Casey Carl, the President of Multichannel
and Senior Vice President, Enterprise Strategy at Target.

Founded in 1999, DermStore offers its products through the online platform
targeting approximately 1 million active consumers. The website showcases more
than 26,000 SKUs and 750 brands such as SkinMedica, SkinCeuticals, Obagi and
Dermalogica. The company in order to extend its wings in the cosmetics and
hair care market recently launched two more websites, hairenvy.com and
blush.com.

Target, in order to augment its presence in key markets, has been attempting
to acquire small businesses and DermStore is the latest addition. Earlier, in
March Target entered into 2 separate transactions to acquire CHEFS Catalog and
assets of Cooking.com to tap the rapidly expanding cooking and kitchenware
market.

Going forward, this Zacks Rank #4 (Sell) stock intends to focus on its core
businesses. The company plans to sustain its remodeling program at existing
general merchandise locations by the addition of an expanded food section
along with a greater assortment of dry dairy and frozen items, improved store
layout and enhancement of in-store shopping experience across departments,
such as apparel, home, beauty, shoes and baby.

Alongside, Target is seeking promising expansion opportunities in
international markets such as Canada and Latin America. Recently, the company
revealed its plans to introduce smaller-format stores called CityTarget,
similar to that of its biggest rival, Wal-Mart Stores Inc. (NYSE:WMT-Free
Report).

Moreover, Target announced its year-round price matching policy with the aim
of offering its patrons the facility to match the prices offered by online
retail giants.

The company will match prices with Amazon.com Inc.'s (Nasdaq:AMZN-Free Report)
Amazon.com, Wal-Mart's Walmart.com, Best Buy Co. Inc.'s (NYSE:BBY-Free Report)
BestBuy.com, and Toysrus.com. Target believes that its price matching policy
coupled with the REDcard reward program would provide it an edge over its
competitors.

Abiomed's Impella Reaches Milestone

Abiomed, Inc. (Nasdaq:ABMD-Free Report) revealed that physicians across the
U.S. have implanted more than 15,000 Impella pumps in patients needing
hemodynamic support. Mercy General Hospital in Sacramento, CA is the place
where the 15,000th Impella procedure took place with an Impella pump that
provided prophylactic circulatory support.

Currently, Impella 2.5 is the Smallest Heart Pump in the world. It is a widely
used and studied percutaneous circulatory support device.

Abiomed also revealed that its higher flow Impella CP device has also been
implanted in more than 1,000 patients globally. The device got the 510(k)
clearance from the Food & Drug Administration (FDA) in Sep last year. The
1,000th Impella CP procedure took place at the Ochsner Medical Center in New
Orleans, LA.

The Impella CP is very useful in treating patients who need percutaneously
deployed hemodynamic support device. It is a vital device in the cardiology
toolbox that can be used at ease.

ABMD is also in the process of developing Impella pediatric device. The device
will be helpful in treating infants and children with heart failure. However,
the device has not yet received clearance from the FDA.

Abiomed is a leading provider of heart support technologies. Its Impella
platform consists of minimally invasive products with flow levels that vary
with device size depending on the patient's need for hemodynamic support.

About 775 hospitals in the U.S. have acquired Impella products, with over
2,000 implanting physicians. Moreover, 66 new hospitals adopted the latest
Impella CP, with 172 customer sites in the U.S.

Abiomed, a Zacks Rank #3 (Hold) stock, reported fiscal 2013-first-quarter
earnings per share of 5 cents (excluding legal expenses and the medical device
excise tax) that missed the Zacks Consensus Estimate by a penny. The quarterly
EPS was lower than the year-ago earnings of 8 cents.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of
the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded
stocks. Our analysts are organized by industry which gives them keen insights
to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978. The later formation of the Zacks Rank, a proprietary stock picking
system; continues to outperform the market by nearly a 3 to 1 margin. The best
way to unlock the profitable stock recommendations and market insights of
Zacks Investment Research is through our free daily email newsletter; Profit
from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED
to be worth your time! Register for your free subscription to Profit from the
Pros.

Get the full Report on TGT - FREE

Get the full Report on WMT - FREE

Get the full Report on AMZN - FREE

Get the full Report on BBY - FREE

Get the full Report on ABMD - FREE

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities
(including a broker-dealer and an investment adviser), which may engage in
transactions involving the foregoing securities for the clients of such
affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment
is the potential for loss. This material is being provided for informational
purposes only and nothing herein constitutes investment, legal, accounting or
tax advice, or a recommendation to buy, sell or hold a security. No
recommendation or advice is being given as to whether any investment is
suitable for a particular investor. It should not be assumedthat any
investments in securities, companies, sectors or markets identified and
described were or will be profitable. All information is current as of the
date of herein andis subject to change without notice. Any views or opinions
expressed may not reflect those of the firm as a whole. Zacks Investment
Research does not engage in investment banking, market making or asset
management activities of any securities. These returns are from hypothetical
portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced
monthly with zero transaction costs. These are not the returns of actual
portfolios of stocks. The S&P 500 is an unmanaged index. Visit
http://www.zacks.com/performance for information about the performance numbers
displayed in this press release.

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com
 
Press spacebar to pause and continue. Press esc to stop.